Tandem Diabetes Care Inc
$ 21.11
5.02%
14 Apr - close price
- Market Cap 1,446,124,000 USD
- Current Price $ 21.11
- High / Low $ 21.12 / 20.05
- Stock P/E N/A
- Book Value 2.27
- EPS -3.19
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.98 %
- 52 Week High 29.65
- 52 Week Low 9.98
About
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$30.62
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-02-21 | 2023-11-01 | 2023-08-03 | 2023-05-03 |
| Reported EPS | -0.01 | -0.31 | -0.78 | -0.6652 | -0.4356 | -0.35 | -0.48 | -0.63 | -0.27 | -0.38 | -0.55 | -1.92 |
| Estimated EPS | -0.092 | -0.32 | -0.4 | -0.6077 | -0.2357 | -0.4 | -0.54 | -0.76 | -0.25 | -0.34 | -0.53 | -0.52 |
| Surprise | 0.082 | 0.01 | -0.38 | -0.0575 | -0.1999 | 0.05 | 0.06 | 0.13 | -0.02 | -0.04 | -0.02 | -1.4 |
| Surprise Percentage | 89.1304% | 3.125% | -95% | -9.4619% | -84.8112% | 12.5% | 11.1111% | 17.1053% | -8% | -11.7647% | -3.7736% | -269.2308% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNDM
2026-04-14 00:39:56
Tandem Diabetes Care Inc (TNDM) shares surged 4.8% to $20.10, although the stock is significantly below its GF Value™ of $32.99, indicating it is undervalued. The company holds a GF Score™ of 74/100, suggesting above-average potential for long-term returns, primarily driven by strong growth prospects (8/10). However, investors are cautioned by low profitability (3/10) and financial strength scores (4/10), coupled with a high P/E ratio compared to its historical median.
2026-04-13 16:39:00
Mizuho Securities has reiterated its "Hold" rating for Tandem Diabetes Care (TNDM.US), maintaining a target price of $22. This suggests the firm sees the current valuation as appropriate without expectations for significant near-term upside or downside based on their analysis.
2026-04-12 23:10:39
This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment with a mid-channel oscillation pattern and offers specific entry, target, and stop-loss zones for long, breakout, and short positions. The analysis includes multi-timeframe signal strengths and key support and resistance levels for various holding periods.
2026-04-11 03:08:00
Representative Gilbert Ray Cisneros, Jr. (D-California) recently purchased between $1,001 and $15,000 worth of shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM). The transaction, which occurred on March 3, 2026, was disclosed on April 7, 2026. This move is subject to public scrutiny due to Cisneros' position as a member of Congress and raises questions about potential conflicts of interest.
2026-04-10 08:10:31
The diabetes care market is projected to reach $43.97 billion by 2030, growing at an 8.6% CAGR, driven by technological advancements and shifting patient preferences. Key trends include the adoption of digital health solutions, continuous glucose monitoring, and personalized treatment approaches. The market is segmented by product type (glucose monitoring and insulin pumps), diabetes type, and end-user, with major companies like F. Hoffmann-La Roche Ltd., Sanofi S.A., and Abbott Laboratories leading the industry.
2026-04-09 19:39:46
Goldman Sachs analyst David Roman has lowered the price target for Tandem Diabetes Care (TNDM) from $28 to $25, while maintaining a 'Neutral' rating. This adjustment reflects a more conservative outlook despite recent upgrades from other analysts. The average target price from 21 analysts is $30.86, suggesting a potential upside of 55.73% from its current price, while GuruFocus estimates a fair value of $35.47, indicating a 79.01% upside.
